“We are thrilled to partner with drug developers to advance predictive biomarkers for NSCLC patient selection for immunotherapy, reaching biologically intelligent image analysis methodology through artificial intelligence,” says Joseph Krueger, PhD, Flagship Biosciences Chief Scientific Officer.
WESTMINSTER, Colo. (PRWEB) June 07, 2018
Flagship Biosciences is proud to co-author the research paper, "PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters," published June 6, 2018, in PLOS ONE, an open access peer-reviewed journal. The article may be accessed here: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196464.
The paper is the first Non-Small Cell Lung Cancer (NSCLC) study adopting Flagship’s cTA digital immunohistochemistry (IHC) platform to report IHC data generated with a pharmaceutical anti-PD-L1 clone used for current antibody development in immuno-oncology.
Using Flagship’s cTA platform to analyze NSCLC tissues from patients with advanced disease allowed for the identification and quantification of multiple immune biomarkers in tumor-nest and tumor microenvironment (TME) compartments in whole sections. The research demonstrated that NSCLC with higher PD-L1 levels were enriched for multiple immune cell biomarkers, indicating escape from host immunity.
However, comparison of manual and digital analyses also indicated the potential for further improving the accuracy and relevance of PD-L1 assays, by differentiating between constitutive and reactive PD-L1 expression patterns rather than using simple cut-off points. This allows for better characterization of the different tissue phenotypes associated with immune cell infiltration and regulation which dictate the variable patient-specific responses of patients who express PD-L1.
“We are thrilled to partner with drug developers to advance predictive biomarkers for NSCLC patient selection for immunotherapy, reaching biologically intelligent image analysis methodology through artificial intelligence,” says Joseph Krueger, PhD, Flagship Biosciences Chief Scientific Officer. “Flagship’s cTA digital immunohistochemistry platform can advance biomarker strategies throughout drug development, from early stage research through patient screening and selection.”
About Flagship Biosciences
Flagship Biosciences helps drug developers confidently define their path to success. Our cTA platform and decision support process for tissue biomarkers applies computational tissue analysis to make timely decisions. For more information on how Flagship accelerates drug development, please visit flagshipbio.com and follow Flagship on Twitter @FlagshipBio.
VP, Sales & Marketing